Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26830426)
Watch
English
Oral antiviral therapies for chronic hepatitis C infection
scientific article
In more languages
default values for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
title
Oral antiviral therapies for chronic hepatitis C infection
(English)
1 reference
stated in
PubMed
main subject
chronic hepatitis C
1 reference
based on heuristic
inferred from title
chronic hepatitis
1 reference
based on heuristic
inferred from title
author name string
S. Pol
series ordinal
1
1 reference
stated in
Crossref
M. Corouge
series ordinal
2
1 reference
stated in
Crossref
P. Sogni
series ordinal
3
1 reference
stated in
Crossref
language of work or name
English
1 reference
stated in
PubMed
publication date
June 2013
1 reference
stated in
PubMed
published in
Therapeutic advances in infectious disease
1 reference
stated in
PubMed
volume
1
1 reference
stated in
PubMed
issue
3
1 reference
stated in
PubMed
page(s)
107-16
1 reference
stated in
PubMed
cites work
Boceprevir for previously treated chronic HCV genotype 1 infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
7 April 2017
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
7 April 2017
Replication of hepatitis C virus
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
7 April 2017
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
7 April 2017
Telaprevir for retreatment of HCV infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
7 April 2017
Telaprevir for previously untreated chronic hepatitis C virus infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
7 April 2017
Boceprevir for untreated chronic HCV genotype 1 infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
7 April 2017
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Anti-HCV drugs in the pipeline
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Antiviral strategies in hepatitis C virus infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Preliminary study of two antiviral agents for hepatitis C genotype 1.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
New targets for antiviral therapy of chronic hepatitis C.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
The NS5A replication complex inhibitors: difference makers?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
EASL Clinical Practice Guidelines: management of hepatitis C virus infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Interferon-lambda: a new addition to an old family
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Cyclophilin inhibitors in hepatitis C viral infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
The hepatitis C virus life cycle as a target for new antiviral therapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 September 2017
Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
31 May 2018
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
31 May 2018
Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Exploratory study of oral combination antiviral therapy for hepatitis C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1177%2F2049936113488359
retrieved
21 January 2018
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040722
retrieved
28 November 2018
A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25165547
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1177/2049936113488359
1 reference
stated in
PubMed
PMC publication ID
4040722
1 reference
stated in
PubMed
PubMed publication ID
25165547
1 reference
stated in
PubMed
ResearchGate publication ID
258190297
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit